EGFR and non-small cell lung carcinoma: Since 2009, the IPASS study5 first prospectively demonstrated the clinical efficacy of EGFR‐ tyrosine kinase inhibitors (TKIs) in patients with advanced NSCLC harboring EGFR mutations.